WO1992005130A1 - NOVEL 1α-HYDROXY VITAMIN D4 AND NOVEL INTERMEDIATES AND ANALOGUES - Google Patents

NOVEL 1α-HYDROXY VITAMIN D4 AND NOVEL INTERMEDIATES AND ANALOGUES Download PDF

Info

Publication number
WO1992005130A1
WO1992005130A1 PCT/US1991/006865 US9106865W WO9205130A1 WO 1992005130 A1 WO1992005130 A1 WO 1992005130A1 US 9106865 W US9106865 W US 9106865W WO 9205130 A1 WO9205130 A1 WO 9205130A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
compound
hydroxy
formula
cyclovitamin
Prior art date
Application number
PCT/US1991/006865
Other languages
French (fr)
Inventor
Joyce C. Knutson
Charles W. Bishop
Robert M. Moriarty
Original Assignee
Lunar Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunar Corporation filed Critical Lunar Corporation
Priority to BR919106062A priority Critical patent/BR9106062A/en
Priority to PL91294706A priority patent/PL170447B1/en
Priority to KR1019920701187A priority patent/KR100231809B1/en
Priority to CA002069084A priority patent/CA2069084C/en
Priority to DK91917288T priority patent/DK0503035T3/en
Priority to DE69132862T priority patent/DE69132862T2/en
Priority to AU85422/91A priority patent/AU650286B2/en
Priority to EP91917288A priority patent/EP0503035B1/en
Publication of WO1992005130A1 publication Critical patent/WO1992005130A1/en
Priority to NO92921955A priority patent/NO921955L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation

Definitions

  • This invention relates to biologically active vitamin D 4 compounds. More specifically, this invention relates to novel l ⁇ -hydroxy vitamin D 4 and novel intermediates used in its synthesis, novel 1,25 dihydroxy vitamin D 4 , and novel 1,24 dihydroxy vitamin D 4 .
  • This invention also relates to a pharmaceutical composition which includes a pharmaceutically effective amount of the novel l ⁇ -hydroxy vitamin D 4 compounds, and to a method of controlling abnormal calcium metabolism by administering a pharmaceutically effective amount of the novel compounds.
  • Vitamin D is known to be important in the regulation of calcium metabolism in animals and man. See, Harrison's Principals of Internal Medicine: Part Eleven, "Disorders of Bone and Mineral Metabolism, Chapter 335," E. Braunwald, et al., (eds.), McGraw-Hill, New York, 1987, pp. 1860-1865.
  • the two most commonly known, useful forms of vitamin D are vitamin D 3 and vitamin D 2 .
  • Vitamin D 3 is synthesized endogenously in the skin of animals and man, whereas vitamin D 2 is the form of vitamin D supplied by plants. Vitamin D 2 differs from vitamin D 3 in that it contains a double bond between C22 and C23 and further contains a C24-methyl group. In man and rats, vitamin D 3 and vitamin D 2 have equivalent biopotency.
  • Vitamin D 4 also known as irradiated 22,23-dihydro- ergosterol or 22,23-dihydro vitamin D 2 or 22,23- dihydroergocalciferol, differs from vitamin D 3 in that it contains a C24 methyl group. Vitamin D 4 was first described in 1936. See, Grab, W. , Z.Phvsiol. Chem. , 243:63 (1936); McDonald, F.G., J. Biol. Chem. , 114:IVX (1936). See also, indaus, A. and Trautmann, G. , Z. Physiol. Chem., 247:185-188 (1937).
  • vitamin D 4 is one-third or three-fourths as active as vitamin D 3 and in the chick, either one-tenth or one-fifth as active as vitamin D 3 .
  • vitamin D 4 was less active than vitamin D 3 .
  • DeLuca, et al. report that, in their hands, vitamin D 4 is two- thirds as active as vitamin D 3 or vitamin D 2 in the rat, and one- fifth as active as vitamin D 3 in the chick.
  • vitamin D 4 has remained "only of academic interest” as applicants are unaware of any further study of vitamin D 4 since that reported by DeLuca, et. al. In fact, The Merck Index states with respect to vitamin D 4 , "Its biological activity seems doubtful.” Merck Index, S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J., (1989) pp. 1579, #9930.
  • novel compounds of the invention are bioactive forms of vitamin D 4 .
  • the present inventors have discovered that these active forms of vitamin D 4 display much greater biopotency than would be predicted on the basis of the previously reported bioassays of vitamin D 4 .
  • the present inventors have also discovered, that the bioactive novel compounds are less toxic than would be predicted on the basis of their biopotency. This combination of high activity with low toxicity makes the compounds of the invention useful as therapeutic agents in the treatment of disorders of calcium metabolism.
  • the novel compounds of the invention are advantageously used as the active compounds of pharmaceutical compositions for diseases induced by abnormal metabolism of calcium.
  • Figure 1 illustrates preparative steps for the synthesis of vitamin D 4 .
  • Figure 2 illustrates preparative steps for the synthesis of l ⁇ -hydroxy vitamin D 4 starting with vitamin D 4 .
  • the present invention provides synthetic l ⁇ -hydroxy vitamin D 4 (l ⁇ -OH-D 4 ) compounds as well as tosylated and cyclic derivatives of vitamin D 4 .
  • biological activity or “biologically active” are meant to refer to biochemical properties of compounds such as affecting metabolism, e.g., affecting serum calcium concentration, or binding to an appropriate receptor protein, e.g., binding to vitamin D recepter protein.
  • the invention encompasses biologically active compounds of the general formula (I) :
  • R 1 is either H or OH
  • R 2 is either H or OH
  • the invention involves the preparation of compounds of formula (I) .
  • Synthesis of l ⁇ -hydroxy vitamin D 4 i.e., compounds of formula (I) wherein R 1 and R 2 are H, is accomplished according to the schema presented in Figures 1 and 2.
  • the synthesis uses ergosterol as the starting material. Ergosterol undergoes side chain saturation in a six-step process to yield 22,23-dihydroergosterol (VIII) using a procedure similar to that of Barton, et al., JCS Perkin I . , 1976, 821-826.
  • the 22,23-dihydroergosterol is then irradiated as described in Windaus, et al. , Z. Physiol.
  • vitamin D 4 [22,23-dihydroergocalciferol] (IX) .
  • IX [22,23-dihydroergocalciferol]
  • vitamin D 4 is then hydroxylated in a four-step process to yield l ⁇ -hydroxy vitamin D 4 using a procedure similar to that described by Paaren, et al., J. Or ⁇ . Chem.. 1980, 45:3253.
  • ergosterol is acetylated to form the 3yS-acetate.
  • This ergosterol acetate is subjeered to hydroxyhalogenation at the 5,6 double bond to form the 6 ⁇ -chloro-5 ⁇ -hydroxy derivative.
  • This chlorohydrin is reduced and reacetylated to the 5 ⁇ -hydroxy (i.e., 5 ⁇ -ol) derivative.
  • the 5 ⁇ -ol is subjected to hydrogenation to saturate the side chain.
  • the resulting 33-acetoxyergost-7en-5 ⁇ -ol is reduced to 22,23 dehydroergosterol acetate which is in turn reduced to yield 22,23 dehydroergosterol.
  • Vitamin D 4 is then tosylated to yield 3?-tosyl vitamin D 4 .
  • the tosylate is displaced by solvolysis to yield the 6-methoxy-3,5-cyclovitamin D 4 .
  • the cyclovitamin D 4 is subjected to allyllic oxidation to form the l ⁇ -hydroxy cyclovitamin derivative.
  • the l ⁇ -hydroxy cyclovitamin derivative is sequentially solvolyzed and subjected to a Diels-Alder-type reaction which removes the 5-methoxy group and separates the l ⁇ -hydroxy vitamin D 4 (5,6-cis) from the 5,6 trans-l ⁇ -hydroxy vitamin D 4 .
  • the 1,24 dihydroxy vitamin D 4 and 1,25 dihydroxy vitamin D 4 metabolites of l ⁇ -hydroxy vitamin D 4 are synthesized by incubating the l ⁇ -hydroxy derivatives with human liver cells, culturing the cells, and recovering the 1,24 dihydroxy or 1,25 dihydroxy vitamin D 4 . Using vitamin D receptor protein binding tests, these metabolites are determined to be biologically active.
  • the compounds of formula (I) have been found to possess valuable pharmacological activity, namely, as controlling agents for calcium metabolism, especially serum calcium concentrations. Specifically, the compounds of formula (I) increase serum calcium concentrations in rats with vitamin D deficiency. It has also been found that the compounds of formula (I) have low toxicity, which enhances their pharmaceutical properties. Compounds of formula (I) have a toxicity, as measured by the LD 5C test, which is similar to that of corresponding vitamin D 2 compounds and lower than that of corresponding vitamin D 3 compounds. Thus, the compounds of the invention are applicable to various clinical and veterinary fields, and are particularly useful for the treatment of abnormal metabolism of calcium and phosphorus.
  • the invention entails a method of controlling calcium metabolism, such as for treating abnormal calcium metabolism caused, e.g., by liver failure, renal failure, gastrointestinal failure, etc.
  • the compounds of formula (I) can be used to treat prophylactically or therapeutically vitamin D deficiency diseases and related diseases, for example, renal osteodystrophy, steatorrhea, anticonvulsant osteomalacia, hypophosphatemic vitamin D- resistant rickets, osteoporosis, including postmenopausal osteoporosis, senile osteoporosis, steriod-induced osteoporosis, and other disease states characteristic of loss of bone mass, pseudodeficiency (vitamin D-dependent) rickets, nutritional and malabsorptive rickets, osteomalacia and osteopenias secondary to hypoparathyroidism, post-surgical hypoparathyroidism, idiopathic hypothyroidism, pseudoparathyroidism, and alcoholism.
  • the compounds of formula (I) are useful as active compounds in pharmaceutical compositions having reduced side effects and low toxicity as compared with the known analogs of active forms of vitamin D 3 , when applied, for example, to diseases induced by abnormal metabolism of calcium.
  • These pharamaceutical compositions constitute another aspect of the invention.
  • the pharmacologically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans.
  • the compounds of formula (I) can be employed in admixtures with conventional excipients, e.g., pharmaceutically acceptable carrier substances suitable for enteral (e.g., oral), parenteral, or topical application which do not deleteriously react with the active compounds.
  • Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils (e.g., corn oil, cottonseed oil, peanut oil, olive oil, coconut oil) , fish liver oils, oily esters such as Polysorbate 80, polyethylene glycols, gelatine, carbohydrates (e.g., lactose, a ylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid onoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc.
  • the pharmaceutical preparations can be sterilized and, if desired, be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or one or more other active compounds, for example, vitamin D 3 or D2 and their l ⁇ -hydroxylated metabolites, conjugated estrogens or their equivalents, anti-estrogens, calcitonin, biphosphonate ⁇ , calcium supplements, cobalomin, pertussis toxin and boron.
  • auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or one or more other active compounds, for example, vitamin D 3 or D2 and their l ⁇ -hydroxylated metabolites, conjugated estrogens or their equivalents, anti-estrogens
  • injectable, sterile solutions preferably oily or aqueous solution
  • suspensions, emulsions, or implants including suppositories.
  • Ampoules are convenient unit dosages.
  • Suitable enteral application particularly suitable are tablets, dragees, liquids, drops, suppositories, lozenges, powders, or capsules.
  • a syrup, elixir, or the like can be used if a sweetened vehicle is desired.
  • Sustained or directed release compositions can also be formulated, e.g., liposome ⁇ or those in which the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.
  • suitable nonsprayable viscous, semi-solid or solid forms can be employed which include a carrier compatible with topical application and having a dynamic viscosity preferably greater than water.
  • suitable formulations include, but are not limited to, solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, aerosols, transdermal patches, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, demulsifiers, wetting agents, etc.
  • compositions for rectal administration, compounds are formed into a pharmaceutical composition containing a suppository base such as cacao oil or other triglycerides.
  • a suppository base such as cacao oil or other triglycerides.
  • the composition advantageously includes an antioxidant such ascorbic acid, butylated hydroxyanisole or hydroquinone.
  • the compounds of this invention are dispensed by unit dosage form comprising about 0.5 ⁇ g to about 25 ⁇ g in a pharmaceutically acceptable carrier per unit dosage.
  • the dosage of the compounds according to this invention generally is about 0.01 to about 0.5 ⁇ g/kg/day, preferably about 0.04 to about 0.3 ⁇ g/kg/day.
  • the actual preferred amounts of active compound in a specific case will vary according to the efficacy of the specific compound employed, the particular compositions formulated, the mode of application, and the particular situs and organism being treated.
  • the specific dose for a particular patient depends on the age, body weight, general state of health, sex, on the diet, on the timing and mode of administration, on the rate of excretion, and on medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compounds and of a known agent, such as by means of an appropriate conventional pharmacological protocol.
  • the compounds of the present invention can also be advantageously used in veterinary compositions, for example, feed compositions for domestic animals to treat or prevent hypocalcemia.
  • the compounds of the present invention are dispensed in animal feed such that normal consumption of such feed provides the animal about 0.01 to about 0.5 ⁇ g/kg/day.
  • Ergosterol (II) was converted to ergosterol acetate (III) by dissolving 100 g (0.25 mol) ergosterol in 600 ml of anhydrous pyridine and 68 ml (0.7 mol) acetic anhydride. The solution was stirred overnight at room temperature after which time the solution was cooled by adding 1.2 L ice, causing a precipitate to form. The precipitate was washed five times with 400 ml portions of water, then once with 400 ml of CH-.CN.
  • Ergosterol acetate (III) (26 gm, 0.062 M) was dissolved in 2.5 L of freshly distilled deoxygenated toluene.
  • 9 ml (0.111 mol) chromyl chloride dissolved in 240 ml dry CH 2 C1 2 was added under nitrogen at -78°C over a thirty minute period.
  • the reaction system was stirred at -78°C for an additional fifteen minutes, and then 62 ml of a saturated solution of sodium borohydride in ethanol was added in one portion. After stirring at -78°C for an additional fifteen minutes, the reaction solution was poured into a two phase system of 3N hydrochloric acid (3L) and benzene (3L) .
  • the ether solution was dried with MgS0 4 , and after filtration, evaporated under reduced pressure to yield a crude product which was converted to a slurry with CH 3 CN (100 ml) .
  • the product was collected by filtration and recrystallized from CH 3 CN to yield 4.5 g.
  • 22,23-dihydroergosterol (VIII) (2.0 g, 5.0 mmol) was dissolved in a solution of diethyl ether and benzene (4:1, 600 ml) and irradiated (Hannovia immersion lamp, 450 watts) with stirring under argon in a water-cooled quartz vessel for three hours. The solution was concentrated in vacuo to yield a gummy solid, which was redissolved in 100 ml. of ethanol and heated at reflux under argon for eight hours.
  • reaction mixture was then diluted with ether (500 ml) and the phases were separated.
  • the organic phase was washed with 10% NaOH (3 x 200 ml) , water (2 x 200 ml) and saturated NaCl solution (2 x 200 ml) , dried over MgS0 4 and concentrated in vacuo.
  • the residue was absorbed on a silica gel column and eluted with 30% ethyl acetate in hexane to afford 0.45 g.
  • mice Male weanling rats (Holtzman strain, Holtzman Company, Madison, Wisconsin) were fed a vitamin D deficient diet containing adequate calcium (0.47%) and phosphorus (0.3%) . Within three to four weeks, this diet induces an extreme vitamin D deficiency characterized by low serum calcium and poor growth. After four weeks on this diet, the rats had serum calcium values less than 7 mg/dl. The rats were then separated into four groups and orally administered either l ⁇ -hydroxy vitamin D 4 in a vehicle such as coconut oil or the vehicle (control) for each of 14 days. Twenty-four hours after the last dose, the rats were killed and the blood calcium measured by a standard laboratory technique. The results of these determinations are shown in Table 1.
  • the acute oral toxicity of l ⁇ -0H-D 4 in rats was assessed by determining the mean lethal dose (LD 50 ) using a well-known method. Rats were fed a standard laboratory diet for 8-10 weeks. Five animals of each sex were administered one oral dose of l ⁇ -OH-D 4 . The animals were observed for 14 days, and the number of deaths noted.
  • the LD 50 value was determined to be about 1.0 mg/kg in nidies and 3.0 irig/kg in females.
  • the l ⁇ -hydroxy vitamin D 4 of the present invention is incubated with cultured human liver cells which metabolize the compound to several products including the metabolite 1,25 dihydroxy vitamin D 4 .
  • the 1,25 metabolite is isolated and purified by high pressure liquid chromatography and identified by gas-chromatography-mass spectrometry. Binding studies demonstrate that the 1,25 dihydroxy vitamin D 4 has good binding affinity for the mammalian vitamin D receptor protein indicating it is biologically active. The procedures used are similar to that described by Strugnell, et. al., Bioche . Pharm. Vol. 40:333-341 (1990) .
  • 1,24 dihydroxy vitamin D is accomplished as described in Example 4, above.
  • the l ⁇ -hydroxy vitamin D 4 of the present invention is incubated with cultured human liver cells which metabolize the compound to several products including the metabolite 1,24 dihydroxy vitamin D 4 .
  • the 1,24 metabolite is isolated and purified using high pressure liquid chromatography and identified by gas-chromatography-mass spectrometry. Binding studies with the new metabolite demonstrate that the metabolite has good binding affinity for the mammalian vitamin D receptor protein which indicates the drug is biologically active.
  • Example 6 Hypercalce ia testing
  • mice Female rats are fed a commercial diet containing 0.8% calcium (0.8%) and phosphorus (0.6%). The rats are divided into four groups and each group is orally administered daily either l ⁇ -OH D 4 in a vehicle such as coconut oil or the vehicle (control) alone for 13 weeks. Twenty-four hours after the last dose, the rats are killed and their serum calcium determined by a standard method.
  • mice Male weanling rats are fed a diet deficient in vitamin D and with low calcium (0.02%). After a period of four weeks has elapsed, the rats are divided into four groups and intravenously administered either l ⁇ -OH D 4 in a vehicle such as ethanol or the vehicle (control) alone. Sixteen hours after administration, the rats are killed and the intestinal calcium transport measured by using everted duodenal sacs, following the method of Martin and DeLuca, Am. J. Phvsiol. 216:1352-1359.
  • a clinical study is conducted with postmenopausal osteoporotic outpatients having ages between 55 and 75 years.
  • the study involves up to 120 patients randomly divided into three treatment groups, and continues for 12 to 24 months.
  • Two of the treatment groups receive constant dosages of l ⁇ -vitamin D 4 (u.i.d.; two different dose levels above 3.0 ⁇ g/day) and the other group receives a matching placebo.
  • All patients maintain a normal intake of dietary calcium (500 to 800 mg/day) and refrain from using calcium supplements.
  • Efficacy is evaluated by pre- and post-treatment comparisons of the patient groups with regard to (a) total body, radial, femoral and/or spinal bone mineral density as determined by x-ray absorptiometry (DEXA) , (b) bone biopsies of the iliac crest, and (c) determinations of serum osteocalcin.
  • Safety is evaluated by comparisons of urinary hydroxyproline excretion, serum and urine calcium levels, creatinine clearance, blood urea nitrogen, and other routine determinations.
  • a clinical study is conducted with healthy postmenopausal women having ages between 55 and 60 years.
  • the study involves up to 80 patients randomly divided into two treatment groups, and continues for 12 to 24 months.
  • One treatment group receives a constant dosage of l ⁇ -vitamin D 4 (u.i.d.; a dose level above 3.0 ⁇ g/day) and the other receives a matching placebo.
  • the study is conducted as indicated in Example 2 above.
  • a twelve-month double-blind placebo-controlled clinical trial is conducted with thirty men and/or women with renal disease who are undergoing chronic hemodialysis. All patients enter an eight-week control period during which time they receive a maintenance dose of vitamin D 3 (400 IU/day) . After this control period, the patients are randomized into two treatment groups: one group receives a constant dosage of l ⁇ -vitamin D 4 (u.i.d.; a dosage greater than 3.0 ⁇ g/day) and the other group receives a matching placebo. Both treatment groups receive a maintenance dosage of vitamin D 3 , maintain a normal intake of dietary calcium, and regrain from using calcium supplements.
  • Efficacy is evaluated by pre- and post-treatment comparisons of the two patient groups with regard to (a) direct measurements of intestinal calcium absorption, (b) total body, radial, femoral and/or spinal bone mineral density, and (c) determinations of serum calcium and osteocalcin. Safety is evaluated by regular monitoring of serum calcium.
  • l ⁇ -vitamin D 4 significantly increases serum osteocalcin levels and intestinal calcium absorption, as determined by measurements using a single or double-isotope technique.
  • Patients treated with this compound show normalized serum calcium levels, stable values for total body, radial, femoral and/or spinal bone densities relative to baseline values.
  • patients treated with placebo show frequent hypocalcemia, significant reductions in total body, radial, femoral and/or spinal bone density. An insignificant incidence of hypercalcemia is observed in the treated group.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Novel 1α-hydroxy vitamin D4 and novel analogues, 1,25 dihydroxy vitamin D4 and 1,24 dihydroxy vitamin D4 which are useful as active compounds of pharmaceutical compositions for the treatment of disorders of calcium metabolism. Preparation of the novel 1α-hydroxy vitamin D4 starts from ergosterol which is converted in six steps to 22,23-dihydroergosterol. 22,23-dihydroergosterol was irradiated to yield vitamin D4 which is converted in four steps to 1α-hydroxy vitamin D4 using a cyclovitamin procedure which produces the novel intermediates, vitamin D4 tosylate, 3,5 cyclovitamin D4 and 1α-hydroxy cyclovitamin D4. 1,25 dihydroxy vitamin D4 and 1,24 dihydroxy vitamin D4 are isolated as biological products of the metabolism of novel 1α-hydroxy vitamin D4 using cultured human liver cells.

Description

NOVEL lα-HYDROXY VITAMIN D4 AND NOVEL INTERMEDIATES AND ANALOGUES
TECHNICAL FIELD
This invention relates to biologically active vitamin D4 compounds. More specifically, this invention relates to novel lα-hydroxy vitamin D4 and novel intermediates used in its synthesis, novel 1,25 dihydroxy vitamin D4, and novel 1,24 dihydroxy vitamin D4.
This invention also relates to a pharmaceutical composition which includes a pharmaceutically effective amount of the novel lα-hydroxy vitamin D4 compounds, and to a method of controlling abnormal calcium metabolism by administering a pharmaceutically effective amount of the novel compounds.
BACKGROUND
Vitamin D is known to be important in the regulation of calcium metabolism in animals and man. See, Harrison's Principals of Internal Medicine: Part Eleven, "Disorders of Bone and Mineral Metabolism, Chapter 335," E. Braunwald, et al., (eds.), McGraw-Hill, New York, 1987, pp. 1860-1865. The two most commonly known, useful forms of vitamin D are vitamin D3 and vitamin D2. Vitamin D3 is synthesized endogenously in the skin of animals and man, whereas vitamin D2 is the form of vitamin D supplied by plants. Vitamin D2 differs from vitamin D3 in that it contains a double bond between C22 and C23 and further contains a C24-methyl group. In man and rats, vitamin D3 and vitamin D2 have equivalent biopotency.
Vitamin D4, also known as irradiated 22,23-dihydro- ergosterol or 22,23-dihydro vitamin D2 or 22,23- dihydroergocalciferol, differs from vitamin D3 in that it contains a C24 methyl group. Vitamin D4 was first described in 1936. See, Grab, W. , Z.Phvsiol. Chem. , 243:63 (1936); McDonald, F.G., J. Biol. Chem. , 114:IVX (1936). See also, indaus, A. and Trautmann, G. , Z. Physiol. Chem., 247:185-188 (1937). These references report some disagreement as to the level of biological activity of the vitamin suggesting that in the rat, vitamin D4 is one-third or three-fourths as active as vitamin D3 and in the chick, either one-tenth or one-fifth as active as vitamin D3.
A more definitive study of the biological activity of vitamin D4 was made by DeLuca, et al., in 1968. DeLuca, et al., Arch. Biochem. Biophys., 124:122-128 (1968) . There, the authors confirmed that vitamin D4 was less active than vitamin D3. DeLuca, et al. , report that, in their hands, vitamin D4 is two- thirds as active as vitamin D3 or vitamin D2 in the rat, and one- fifth as active as vitamin D3 in the chick.
DeLuca, et al., make reference to the fact that "[t]he synthesis of vitamin D4 has apparently been little used since it was first described by Windhaus and Trautmann," and comment, n[t]his is perhaps due to the fact that vitamin D4 is only of academic interest."
To applicants' knowledge, vitamin D4 has remained "only of academic interest" as applicants are unaware of any further study of vitamin D4 since that reported by DeLuca, et. al. In fact, The Merck Index states with respect to vitamin D4, "Its biological activity seems doubtful." Merck Index, S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J., (1989) pp. 1579, #9930.
Since DeLuca, et. al., discovered the active form of vitamin D3, 1,25-dihydroxy vitamin D3, (U.S. Patent No. 3,697,559) and its synthetic precursor, lα-hydroxy vitamin D3, (U.S. Patent 3,741,996), most interest has centered on developing therapeutic uses of these active vitamin D3 metabolites. Unfortunately, while the vitamin D3 metabolites held great promise as therapeutic agents, this promise has never been fully realized because of the extreme toxicity of these agents. For example, toxicity limits the efficacy of vitamin D3, its active forms and analogs, to prevent bone loss or restore lost bone. Many studies indicate that at dosages required for these agents to be effective in bone loss prevention or restoration, hypercalcemia and hypercalciuria are problems. It has been reported that lα-hydroxy vitamin D3 at a daily dose of 2 μg/day (which has been shown in some studies to be effective in preventing loss of bone) causes toxicity in approximately 67% of patients. What is needed is a biopotent vitamin D metabolite of low toxicity, such that the drug is practical as a therapeutic agent.
SUMMARY OP THE INVENTION
The novel compounds of the invention, lα-hydroxy vitamin D4, 1, 25-dihydroxy vitamin D4 and 1,24-dihydroxy vitamin D4, are bioactive forms of vitamin D4. The present inventors have discovered that these active forms of vitamin D4 display much greater biopotency than would be predicted on the basis of the previously reported bioassays of vitamin D4. The present inventors have also discovered, that the bioactive novel compounds are less toxic than would be predicted on the basis of their biopotency. This combination of high activity with low toxicity makes the compounds of the invention useful as therapeutic agents in the treatment of disorders of calcium metabolism. The novel compounds of the invention are advantageously used as the active compounds of pharmaceutical compositions for diseases induced by abnormal metabolism of calcium.
In order to study the novel compounds of the invention, it was necessary to develop processes for their production. One alpha-hydroxy vitamin D4 was made synthetically and in the course of that synthesis, novel intermediates were also produced. 1, 25-dihydroxy vitamin D4 and 1,24-dihydroxy vitamin D4 are isolated as biological products of the metabolism of lα-hydroxy vitamin D4.
Other advantages and a fuller appreciation of the specific adaptations, compositional variations, and physical and chemical attributes of the present invention will be gained upon an examination of the following detailed description of the invention, taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will hereinafter be described in conjunction with the appended drawings, wherein like designations refer to like elements throughout and in which:
Figure 1 illustrates preparative steps for the synthesis of vitamin D4; and
Figure 2 illustrates preparative steps for the synthesis of lα-hydroxy vitamin D4 starting with vitamin D4. DETAILED DESCRIPTION
The present invention provides synthetic lα-hydroxy vitamin D4 (lα-OH-D4) compounds as well as tosylated and cyclic derivatives of vitamin D4.
As used herein, the terms "biological activity" or "biologically active" are meant to refer to biochemical properties of compounds such as affecting metabolism, e.g., affecting serum calcium concentration, or binding to an appropriate receptor protein, e.g., binding to vitamin D recepter protein.
In one of its aspects, the invention encompasses biologically active compounds of the general formula (I) :
Figure imgf000006_0001
C D wherein R1 is either H or OH, and R2 is either H or OH, and salts, hydrates and solvates thereof. Preferred compounds among those of formula (I) are those in which R1 and R2 are both H; R1 = OH and R2 = H; and R1 = H and R2 = OH.
In another aspect, the invention involves the preparation of compounds of formula (I) . Synthesis of lα-hydroxy vitamin D4, i.e., compounds of formula (I) wherein R1 and R2 are H, is accomplished according to the schema presented in Figures 1 and 2. As seen in Figure 1, the synthesis uses ergosterol as the starting material. Ergosterol undergoes side chain saturation in a six-step process to yield 22,23-dihydroergosterol (VIII) using a procedure similar to that of Barton, et al., JCS Perkin I., 1976, 821-826. The 22,23-dihydroergosterol is then irradiated as described in Windaus, et al. , Z. Physiol. Chem., 1937, 147:185, to yield vitamin D4 [22,23-dihydroergocalciferol] (IX) . As seen in Figure 2, vitamin D4 is then hydroxylated in a four-step process to yield lα-hydroxy vitamin D4 using a procedure similar to that described by Paaren, et al., J. Orα. Chem.. 1980, 45:3253.
Specifically, ergosterol is acetylated to form the 3yS-acetate. This ergosterol acetate is subjeered to hydroxyhalogenation at the 5,6 double bond to form the 6α-chloro-5α-hydroxy derivative. This chlorohydrin is reduced and reacetylated to the 5α-hydroxy (i.e., 5α-ol) derivative. The 5α-ol is subjected to hydrogenation to saturate the side chain. The resulting 33-acetoxyergost-7en-5α-ol is reduced to 22,23 dehydroergosterol acetate which is in turn reduced to yield 22,23 dehydroergosterol. The 22,23 dehydroergosterol is then irradiated to form vitamin D4. Vitamin D4 is then tosylated to yield 3?-tosyl vitamin D4. The tosylate is displaced by solvolysis to yield the 6-methoxy-3,5-cyclovitamin D4. The cyclovitamin D4 is subjected to allyllic oxidation to form the lα-hydroxy cyclovitamin derivative. The lα-hydroxy cyclovitamin derivative is sequentially solvolyzed and subjected to a Diels-Alder-type reaction which removes the 5-methoxy group and separates the lα-hydroxy vitamin D4 (5,6-cis) from the 5,6 trans-lα-hydroxy vitamin D4.
The 1,24 dihydroxy vitamin D4 and 1,25 dihydroxy vitamin D4 metabolites of lα-hydroxy vitamin D4, are synthesized by incubating the lα-hydroxy derivatives with human liver cells, culturing the cells, and recovering the 1,24 dihydroxy or 1,25 dihydroxy vitamin D4. Using vitamin D receptor protein binding tests, these metabolites are determined to be biologically active.
The compounds of formula (I) have been found to possess valuable pharmacological activity, namely, as controlling agents for calcium metabolism, especially serum calcium concentrations. Specifically, the compounds of formula (I) increase serum calcium concentrations in rats with vitamin D deficiency. It has also been found that the compounds of formula (I) have low toxicity, which enhances their pharmaceutical properties. Compounds of formula (I) have a toxicity, as measured by the LD5C test, which is similar to that of corresponding vitamin D2 compounds and lower than that of corresponding vitamin D3 compounds. Thus, the compounds of the invention are applicable to various clinical and veterinary fields, and are particularly useful for the treatment of abnormal metabolism of calcium and phosphorus.
In a further aspect, the invention entails a method of controlling calcium metabolism, such as for treating abnormal calcium metabolism caused, e.g., by liver failure, renal failure, gastrointestinal failure, etc. The compounds of formula (I) can be used to treat prophylactically or therapeutically vitamin D deficiency diseases and related diseases, for example, renal osteodystrophy, steatorrhea, anticonvulsant osteomalacia, hypophosphatemic vitamin D- resistant rickets, osteoporosis, including postmenopausal osteoporosis, senile osteoporosis, steriod-induced osteoporosis, and other disease states characteristic of loss of bone mass, pseudodeficiency (vitamin D-dependent) rickets, nutritional and malabsorptive rickets, osteomalacia and osteopenias secondary to hypoparathyroidism, post-surgical hypoparathyroidism, idiopathic hypothyroidism, pseudoparathyroidism, and alcoholism. The compounds of formula (I) , preferably those wherein Rl or R2 is OH, such as lα,24 dihydroxy vitamin D4, are of value for the treatment of hyperproliterative skin disorders such as psoriasis.
The compounds of formula (I) are useful as active compounds in pharmaceutical compositions having reduced side effects and low toxicity as compared with the known analogs of active forms of vitamin D3, when applied, for example, to diseases induced by abnormal metabolism of calcium. These pharamaceutical compositions constitute another aspect of the invention.
The pharmacologically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. For example, the compounds of formula (I) can be employed in admixtures with conventional excipients, e.g., pharmaceutically acceptable carrier substances suitable for enteral (e.g., oral), parenteral, or topical application which do not deleteriously react with the active compounds.
Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils (e.g., corn oil, cottonseed oil, peanut oil, olive oil, coconut oil) , fish liver oils, oily esters such as Polysorbate 80, polyethylene glycols, gelatine, carbohydrates (e.g., lactose, a ylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid onoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc.
The pharmaceutical preparations can be sterilized and, if desired, be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or one or more other active compounds, for example, vitamin D3 or D2 and their lα-hydroxylated metabolites, conjugated estrogens or their equivalents, anti-estrogens, calcitonin, biphosphonateε, calcium supplements, cobalomin, pertussis toxin and boron.
For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solution, as well as suspensions, emulsions, or implants, including suppositories. Ampoules are convenient unit dosages.
For enteral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, lozenges, powders, or capsules. A syrup, elixir, or the like can be used if a sweetened vehicle is desired.
Sustained or directed release compositions can also be formulated, e.g., liposomeε or those in which the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.
For topical application, suitable nonsprayable viscous, semi-solid or solid forms can be employed which include a carrier compatible with topical application and having a dynamic viscosity preferably greater than water. Suitable formulations include, but are not limited to, solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, aerosols, transdermal patches, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, demulsifiers, wetting agents, etc.
For rectal administration, compounds are formed into a pharmaceutical composition containing a suppository base such as cacao oil or other triglycerides. To prolong storage life, the composition advantageously includes an antioxidant such ascorbic acid, butylated hydroxyanisole or hydroquinone.
Oral administration of the pharmaceutical compositions of the present invention is preferred. Generally, the compounds of this invention are dispensed by unit dosage form comprising about 0.5 μg to about 25 μg in a pharmaceutically acceptable carrier per unit dosage. The dosage of the compounds according to this invention generally is about 0.01 to about 0.5 μg/kg/day, preferably about 0.04 to about 0.3 μg/kg/day.
It will be appreciated that the actual preferred amounts of active compound in a specific case will vary according to the efficacy of the specific compound employed, the particular compositions formulated, the mode of application, and the particular situs and organism being treated. For example, the specific dose for a particular patient depends on the age, body weight, general state of health, sex, on the diet, on the timing and mode of administration, on the rate of excretion, and on medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compounds and of a known agent, such as by means of an appropriate conventional pharmacological protocol.
In a still further aspect, the compounds of the present invention can also be advantageously used in veterinary compositions, for example, feed compositions for domestic animals to treat or prevent hypocalcemia. Generally, the compounds of the present invention are dispensed in animal feed such that normal consumption of such feed provides the animal about 0.01 to about 0.5 μg/kg/day.
The following examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. In the following examples, all temperatures are set forth in degrees Celsius; unless otherwise indicated, all parts and percentages are by weight. Proton nuclear magnetic (1H NMR) spectra were recorded with an IBM Sy-200(200 mHz) and a Bruker A —400(400 mHz) with aspect 3000 Computer in CDC13 solutions with CHC13 as an internal standard. Infrared spectra were recorded with a Fourier transform (FTIR) using samples as potassium bromide (KBr) pellets or as liquids. Mass spectra were recorded with a Finnigan MAT-90 mass spectrometer at 20 eV/CI. Melting points are determined on a Hoover-Thomas (capillary) Uni-Melt and a Fisher-Johns melting point apparatus (cover-slip type) .
Example 1: Synthesis of lα-hydroxy vitamin D4
Ergosterol (II) was converted to ergosterol acetate (III) by dissolving 100 g (0.25 mol) ergosterol in 600 ml of anhydrous pyridine and 68 ml (0.7 mol) acetic anhydride. The solution was stirred overnight at room temperature after which time the solution was cooled by adding 1.2 L ice, causing a precipitate to form. The precipitate was washed five times with 400 ml portions of water, then once with 400 ml of CH-.CN. The resulting product was air dried to yield 79 g (71%) of ergosterol acetate as a white crystalline solid and had the following characteristics: melting point (m.p.): 169-171°C; 1H NMR: (400 MHz, CDC13) , <5ppm 2.05 (3H, s, 3?-CH3CO) , 4.65-4.75 (1H, m, 3α-H) 5.15-5.25 (2H, m, 22-H and 23-H) , 5.4 (1H, d, 6-H) , 5.6 (1H, d, 7-H) ; FTIR [KBr] : 1734 cm"1 (C=0 stretching) 968 cm"1 (C-H bending) .
Ergosterol acetate (III) (26 gm, 0.062 M) was dissolved in 2.5 L of freshly distilled deoxygenated toluene. To this solution 9 ml (0.111 mol) chromyl chloride dissolved in 240 ml dry CH2C12 was added under nitrogen at -78°C over a thirty minute period. The reaction system was stirred at -78°C for an additional fifteen minutes, and then 62 ml of a saturated solution of sodium borohydride in ethanol was added in one portion. After stirring at -78°C for an additional fifteen minutes, the reaction solution was poured into a two phase system of 3N hydrochloric acid (3L) and benzene (3L) . The organic layer was separated, then washed with water (2L) , twice with a brine solution (2 x 1L) and then dried with anhydrous MgS04. The dried solution was filtered and concentrated in vacuo. The crude crystalline product was then treated with CH3CN (280ml) and filtration of the thus formed slurry yielded 12.5 g (41%) of white crystalline 3jS-Acetoxy-6α-chloroergosta-7,22-dien-5α-ol (IV) and had the following characteristics: m.p.: 190-192°C; 1H NMR: (400 MHz, CDCl3) , δppm 2.05 (3H, s, 30-OAc) , 4.65 (1H, d, 6/3-H) , 5.1 (1H, s, 7-H) , 5.1-5.3 (2H, , 22-H and 23-H) ; FTIR [KBr] : 1732 cm"1 (C=0 stretching) , 968 cm"1 (C-H bending) , 3437 cm"1 (O-H stretching) .
The 3β-Acetoxy 6α-chloroergosta-7,22-dien-5α-ol (IV) (21.4 g, 0.044 mol) in dry THF (900 ml) was added slowly to a stirred suspension of lithium aluminium hydride (2.66 g, 0.07 mol) in dry THF (750 ml) at room temperature under nitrogen. The mixture was refluxed for three hours and cooled to 0°C. Excess hydride was decomposed with saturated Na2S04 solution. Filtration through anhydrous Na2S04 and evaporation of the filtrate gave a solid, which was treated directly with acetic anhydride (110 ml) and dry pyridine (220 ml) at 0°C. Removal of solvent under reduced pressure yielded the acetate (12.75 g, 61%), 3/3-Acetoxyergosta-7,22-dien-5α-ol (V) and had the following characteristics: _m.p. : 229-232°C; FTIR [KBr] 1736 cm"1 (C=0 stretching) , 3460 cm'1 (O-H stretching) , 972 cm"1 (C-H bending) .
3β-Acetoxyergosta-7,22-dien-5α-ol (V) (2.5 g, 0.0055 mol) was shaken for sixteen hours with freshly prepared Pt02 (0.5 g) in ethyl acetate (820 ml) under H2 gas (15 psi) . The catalyst was removed by filtration and evaporation of the filtrate gave the crude acetate which was dissolved in CH2C12 and chromatographed on silica gel. Elution with CH2C12 gave substantially pure 33-Acetoxyergost-7-en-5α-ol (VI) (2.15 g, 85%) as a white crystalline material and had the following characteristics: m.p.: 228-232°C; 1H NMR: (400 MHz, CDC13) , Sppm 2.05 (3H, s, 33-OAc) , 5.05-5.20 (2H, , 3α-H and 7-H) ; FTIR [KBr] : 1736 cm'1 (C=0 stretching) , 3462 cm"1 (O-H stretching) .
Redistilled thionyl chloride (9.7 ml) in dry pyridine (170 ml) was added to compound 30-Acetoxyergost-7-en-5α-ol (VI) (12.0 g, 0.0262 mol) in dry pyridine (800 ml) at 0°C under nitrogen. After 2.5 hours, the solution was diluted with ice cold H20 (1.5 L) and extracted with two portions of ether (2.5 L + 1.5 L) . The combined ether extracts were washed with a NaHC03 solution (1.0 L x 2), then IN HC1 (1.5 L x 2) and then water (1 L) . The ether solution was dried with MgS04, and after filtration, evaporated under reduced pressure to yield a crude product which was converted to a slurry with CH3CN (100 ml) . The product was collected by filtration and recrystallized from CH3CN to yield 4.5 g. (39%) of a white crystalline 22,23-dihydroergosteryl acetate (VII) and had the following characteristics: m.p.: 144- I47=C; H NMR: (400 MHz, CDC13) , δpprn 2.05 (3H, s , 35-OAc) , 4.65-4.75 (IH, m, 3α-H) , 5.4 (IH, d, 6-H) , 5.6 (IH, d, 7-H) ; FTIR [KBr] : 1734 cm"1 (C=0 stretching) .
22,23-dihydroergosteryl acetate (VII) (4.8 g, 0.011 mol) was added at once to a stirred suspension of lithium aluminium hydride (2.5 g, 0.066 mol) in dry ether (1.1 L) at room temperature. The mixture was stirred for two hours at room temperature. 5N NaOH was added to destroy excess lithium aluminium hydride and H20 (500 ml) was then added. The aqueous solution was then extracted with four 250 ml portions of ether. The combined ether extracts and combined organic layer were washed with brine solution (1 L) , then dried with Na2Sθ4. Evaporation of ether under reduced pressure gave the compound, 22,23-dihydroergosterol, (VIII) (4.1 g, 94%) as a white crystalline material and had the following characteristics: m.p.: 147-150°C; 1H NMR: (400 MHz, CDC13) , όppm 3.6-3.7 (IH, , 3α-H) , 5.4 (IH, d, 6H) , 5.6 (IH, d, 7-H) ; FTIR [KBr]: 3400 cm"1 (O-H stretching) .
22,23-dihydroergosterol (VIII) (2.0 g, 5.0 mmol) was dissolved in a solution of diethyl ether and benzene (4:1, 600 ml) and irradiated (Hannovia immersion lamp, 450 watts) with stirring under argon in a water-cooled quartz vessel for three hours. The solution was concentrated in vacuo to yield a gummy solid, which was redissolved in 100 ml. of ethanol and heated at reflux under argon for eight hours. Then, the solution was concentrated in vacuo and the residue was adsorbed on a silica gel column and eluted with 30% ethyl acetate in hexane to afford vitamin D4 (22,23-dihydroergocalciferol) (IX) with a yield of 1.2 g. (60%) and with the following characteristics: 1H NMR: (400 MHz, CDC13) , δppm 0.55 (3H, s, 18-H3) 0.78 (6H, dd, 26-H3 and 27-H3) 0.87 (3H, d, 21-H3) 0.93 (3H, d, 28-H3) 3.94 (IH, m, 3-H) 4.82 (IH, m (sharp), 19-H) , 5.04 (IH, m (sharp), 19-H) , 6.04 (IH, d, 7-H) 6.24 (IH, d, 6-H) .
To a stirred solution of vitamin D4 (IX) (3.0 g, 7.5 mmol) in 10 ml of dry pyridine was added freshly recrystallized p- toluenesulfonyl chloride (3.6 g, 19 mmol) at 0°C. The reaction mixture was stirred at 5°C for 24 hours, and was then quenched by pouring the mixture over ice and saturated NaHC03 (100 ml) with stirring. The aqueous suspension was extracted with CH2C12 (3 x 300 ml) . The combined organic extracts were washed with 10% HCl (3 x 200 ml) , saturated NaHC03 (3 x 200 ml) and saturated NaCl (2 x 200 ml) , dried over MgS04 and concentrated j-n vacuo to yield 3.5 g. (84%) of the novel intermediate compound vitamin D tosylate (X) and had the following characteristics: H NMR (400 MHz, CDC13) , δppm 0.54 (3H, s, 18-H3) 0.78 (6H, dd, 26-H3 and 27- H3) 0.87 (3H, d, 21-H3) , 0.96 (3H, d, 28-H3) 2.45 (3H, s, CH3 (tosylate) 4.68 (3H, m, 3-H) 4.82 (IH, m (sharp), 19-H) 5.04 (IH, m (sharp), 19-H) , 5.95 (IH, d 7-H) , 6.09 (IH, d, 6-H) 7.34 and 7.79 (4H, d, aromatic).
To a stirred suspension of NaHC03 (17.0 g, 202 mmol) in methanol (200 ml) a solution of vitamin D4 tosylate (X) (3.5 g, 6.3 mmol) in dry CH2C12 (10 ml) was added dropwise. The reaction mixture was refluxed overnight under argon, and then cooled to room temperature and concentrated .in vacuo to about 50 ml. The reaction concentrate was diluted with ether (600 ml) , washed with water (3 x 300 ml) , dried over MgS04 and concentrated in vacuo. The residue was passed through a silica gel column and eluted with 10% ethyl acetate in hexane to afford the novel intermediate compound 3,5 cyclovitamin D4 (XI) (heavy oil) with a yield of 1.5 g. (58%) and had the following characteristics: 1H NMR (400 MHz, CDC13) , δppm 0.56 (3H, s, 18-H3) 0.78 (6H, dd, 26-H3 and 27-H3) , 0.87 (3H, d, 21-H3) , 0.94 (3H, d, 28-H3) , 3.28 (3H, ε, OCH3) 4.2 (IH, d, 6-H) , 4.91 (IH, m (sharp), 19-H) , 4.98 (IH, d 7-H) , 5.08 (IH, m (sharp), 19-H) .
Anhydrous tert-butyl hydroperoxide in toluene (3M) (2.6 ml, 7.8 mmol) was added to a stirred suspension of selenium dioxide (0.22 g, 2 mmol) in dry CH2C12 (150 ml) in a three necked flask. The mixture was stirred for three hours under argon. Pyridine (0.3 ml, 3.7 mmol) was then added, and cyclovitamin D4 (XI) (1.5 g, 3.6 mmol) was then introduced as a solution in CH2C12 (50 ml). After stirring for thirty minutes, 10% aqueous NaOH solution (200 ml) was added. The reaction mixture was then diluted with ether (500 ml) and the phases were separated. The organic phase was washed with 10% NaOH (3 x 200 ml) , water (2 x 200 ml) and saturated NaCl solution (2 x 200 ml) , dried over MgS04 and concentrated in vacuo. The residue was absorbed on a silica gel column and eluted with 30% ethyl acetate in hexane to afford 0.45 g. (29%) of the novel intermediate compound lα-hydroxy 3,5- cyciovita in D4 (XII) (oil) and had the following characteristics: 1H NMR (400 MHz, CDC13) , δppm 0.54 (3H, s_, 18- H3) 0.78 (6H, dd, 26-H3 and 27-H3) 0.86 (3H, d, 21-H3) 0.95 (3H, d, 28-H3) 3.26 (3H, s, 0CH3) 4.2 (IH, d, 6-H) , 4.22 (IH, m, 1-H) , 4.95 (IH, d 7-H) , 5.18 (IH, d, 19-H) 5.25 (IH, d, 19-H) .
A solution of lα-hydroxy 3,5-cyclovitamin D4 (XII) (0.45 g, 1.05 mmol) in a solution of dimethyl sulfoxide (4.5 ml) and glacial acetic acid (3.6 ml) was heated to 50°C under argon for one hour. The reaction mixture was then poured over ice and saturated NaHC03 solution (100 ml) , and extracted with ether (3 x 200 ml) . The combined ether extracts were washed with saturated NaHC03 solution (3 x 200ml) , water (3 x 200 ml) and saturated NaCl solution (3 x 200 ml) , dried over MgS04, concentrated in vacuo to give a mixture containing 5,6-cis and 5,6-trans lα- hydroxy vitamin D4 (about 4:1 by 1H NMR) with a yield of 0.4g, (92%). The mixture of 5,6-cis and 5,6-trans lα-hydroxy vitamin D4 (0.4 g, 0.97 mmol) was dissolved in ethyl acetate (25 ml) and treated with freshly recrystallized maleic anhydride (0.08 g, 0.8 mmol). This reaction mixture was heated to 35°C under argon for 24 hours. After evaporation of the solvent jLn vacuo, the crude mixture was chromatographed over a silica gel column using ethyl acetate and hexane (1:1) as eluent, to afford the novel active form of vitamin D4, 5,6-cis lα-hydroxy vitamin D4 (XIII) with a yield of 90 mg (23%) and had the following characteristics: m.p.: 128-130°C; IR v^ (Neat) : 3400 cm"1 (OH stretching); 1H NMR (400 MHz, CDC13) , δppm 0.55 (3H, s, 18-H) 0.79 (6H, dd, 26-H3 and 27-H3) 0.87 (3H, d, 21-H3) 0.94 (3H, d, 28-H3) , 4.24 (IH, m, 3-H) , 4.44 (IH, m, 1-H) , 5.02 (IH, m (sharp), 19-H) , 5.34 (IH, m (sharp), 19-H) , 6.02 (IH, d 7-H) , 6.4 (IH, d, 6-H) ; Mass spectrum [CI] m/e (relative intensity) : 415 (M+l, 41%) 397, (M+l-OH 100%), 379 (27%) , 135 (22%) .
Example 2: Biological testing of lα-hydroxy vitamin D4
Male weanling rats (Holtzman strain, Holtzman Company, Madison, Wisconsin) were fed a vitamin D deficient diet containing adequate calcium (0.47%) and phosphorus (0.3%) . Within three to four weeks, this diet induces an extreme vitamin D deficiency characterized by low serum calcium and poor growth. After four weeks on this diet, the rats had serum calcium values less than 7 mg/dl. The rats were then separated into four groups and orally administered either lα-hydroxy vitamin D4 in a vehicle such as coconut oil or the vehicle (control) for each of 14 days. Twenty-four hours after the last dose, the rats were killed and the blood calcium measured by a standard laboratory technique. The results of these determinations are shown in Table 1.
TABLE 1 s Serum Calcium Concentration
Figure imgf000016_0001
The data of Table 1 indicate that lα-hydroxy vitamin D4 is effective at increasing serum calcium in the vitamin D deficient rat and that the response appears to be dose dependent. Surprisingly, the level of the response appears to compare favorably to that reported by Wientroub, et. al., for 1,25 dihydroxy vitamin D3 administered to vitamin D deficient rats under experimental conditions similar to those described above. See. Wientroub, S., Price, P.A., Reddi, A.H., "The Dichotomy in the Effects of 1,25 dihydroxy vitamin D3 and 24,25 dihydroxy vitamin D3 on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in vitamin D-Deficient Rats," Calcif. Tissue Int. (1987) 40:166-172.
Example 3: Toxicity tests
The acute oral toxicity of lα-0H-D4 in rats was assessed by determining the mean lethal dose (LD50) using a well-known method. Rats were fed a standard laboratory diet for 8-10 weeks. Five animals of each sex were administered one oral dose of lα-OH-D4. The animals were observed for 14 days, and the number of deaths noted. The LD50 value was determined to be about 1.0 mg/kg in nidies and 3.0 irig/kg in females.
For comparison, the LD50 value for lα-hydroxy vitamin D2 under the same conditions was found by applicant's to be 1.7 and 1.8 mg/kg. in male and female rats, respectively. The toxicity of lα-hydroxy vitamin D2 has previously been reported as less than lα-hydroxy vitamin D3. Sjoden, G. , Smith, C. , Lindgren, U. , and DeLuca, H.F., Proc. Soc. Experimental Biol. Med. , 178:432- 436 (1985).
Example 4: Generation and Isolation of 1,25-dihydroxy vitamin D4
The lα-hydroxy vitamin D4 of the present invention is incubated with cultured human liver cells which metabolize the compound to several products including the metabolite 1,25 dihydroxy vitamin D4. The 1,25 metabolite is isolated and purified by high pressure liquid chromatography and identified by gas-chromatography-mass spectrometry. Binding studies demonstrate that the 1,25 dihydroxy vitamin D4 has good binding affinity for the mammalian vitamin D receptor protein indicating it is biologically active. The procedures used are similar to that described by Strugnell, et. al., Bioche . Pharm. Vol. 40:333-341 (1990) .
Example 5: Generation and isolation of 1,24-dihydroxy vitamin D4
Generation and isolation of 1,24 dihydroxy vitamin D is accomplished as described in Example 4, above. The lα-hydroxy vitamin D4 of the present invention is incubated with cultured human liver cells which metabolize the compound to several products including the metabolite 1,24 dihydroxy vitamin D4. The 1,24 metabolite is isolated and purified using high pressure liquid chromatography and identified by gas-chromatography-mass spectrometry. Binding studies with the new metabolite demonstrate that the metabolite has good binding affinity for the mammalian vitamin D receptor protein which indicates the drug is biologically active. Example 6: Hypercalce ia testing
Female rats are fed a commercial diet containing 0.8% calcium (0.8%) and phosphorus (0.6%). The rats are divided into four groups and each group is orally administered daily either lα-OH D4 in a vehicle such as coconut oil or the vehicle (control) alone for 13 weeks. Twenty-four hours after the last dose, the rats are killed and their serum calcium determined by a standard method.
This procedure demonstrates that the serum calcium concentration is unaffected or only slightly elevated at doses lα-0H-D4 up to 2.5 μg/kg/day.
Example 7: Further biological testing
Male weanling rats are fed a diet deficient in vitamin D and with low calcium (0.02%). After a period of four weeks has elapsed, the rats are divided into four groups and intravenously administered either lα-OH D4 in a vehicle such as ethanol or the vehicle (control) alone. Sixteen hours after administration, the rats are killed and the intestinal calcium transport measured by using everted duodenal sacs, following the method of Martin and DeLuca, Am. J. Phvsiol. 216:1352-1359.
Following this procedure demonstrates stimulation of intestinal calcium transport in a dose dependent manner.
Example 8:
A clinical study is conducted with postmenopausal osteoporotic outpatients having ages between 55 and 75 years. The study involves up to 120 patients randomly divided into three treatment groups, and continues for 12 to 24 months. Two of the treatment groups receive constant dosages of lα-vitamin D4 (u.i.d.; two different dose levels above 3.0 μg/day) and the other group receives a matching placebo. All patients maintain a normal intake of dietary calcium (500 to 800 mg/day) and refrain from using calcium supplements. Efficacy is evaluated by pre- and post-treatment comparisons of the patient groups with regard to (a) total body, radial, femoral and/or spinal bone mineral density as determined by x-ray absorptiometry (DEXA) , (b) bone biopsies of the iliac crest, and (c) determinations of serum osteocalcin. Safety is evaluated by comparisons of urinary hydroxyproline excretion, serum and urine calcium levels, creatinine clearance, blood urea nitrogen, and other routine determinations.
This study demonstrates that patients treated with iα-vitamin D4 exhibit significantly higher total body, radial, femoral and/or spinal bone densities relative to patients treated with placebo. The treated patients also exhibit significant elevations in serum osteocalcin. Bone biopsies from the treated patients show that lα-vitamin D4 stimulates normal bone formation. The monitored safety parameters confirm an insignificant incidence of hypercalcemia or hypercalciuria, or any other metabolic disturbance with lα-vitamin D4 therapy.
Example 9:
A clinical study is conducted with healthy postmenopausal women having ages between 55 and 60 years. The study involves up to 80 patients randomly divided into two treatment groups, and continues for 12 to 24 months. One treatment group receives a constant dosage of lα-vitamin D4 (u.i.d.; a dose level above 3.0 μg/day) and the other receives a matching placebo. The study is conducted as indicated in Example 2 above.
This study demonstrates that patients treated with lα-vitamin D4 exhibit reduced losses in total body, radial, femoral and/or spinal bone densities relative to baseline values. In contrast, patients treated with placebo show significant losses in these parameters relative to baseline values. The monitored safety parameters confirm the safety of long-term lα-vitamin D4 administration at this dose level.
Example 10:
A twelve-month double-blind placebo-controlled clinical trial is conducted with thirty men and/or women with renal disease who are undergoing chronic hemodialysis. All patients enter an eight-week control period during which time they receive a maintenance dose of vitamin D3 (400 IU/day) . After this control period, the patients are randomized into two treatment groups: one group receives a constant dosage of lα-vitamin D4 (u.i.d.; a dosage greater than 3.0 μg/day) and the other group receives a matching placebo. Both treatment groups receive a maintenance dosage of vitamin D3, maintain a normal intake of dietary calcium, and regrain from using calcium supplements. Efficacy is evaluated by pre- and post-treatment comparisons of the two patient groups with regard to (a) direct measurements of intestinal calcium absorption, (b) total body, radial, femoral and/or spinal bone mineral density, and (c) determinations of serum calcium and osteocalcin. Safety is evaluated by regular monitoring of serum calcium.
Analysis of the clinical data shows that lα-vitamin D4 significantly increases serum osteocalcin levels and intestinal calcium absorption, as determined by measurements using a single or double-isotope technique. Patients treated with this compound show normalized serum calcium levels, stable values for total body, radial, femoral and/or spinal bone densities relative to baseline values. In contract, patients treated with placebo show frequent hypocalcemia, significant reductions in total body, radial, femoral and/or spinal bone density. An insignificant incidence of hypercalcemia is observed in the treated group.
While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions, that may be made in what has been described. Accordingly, it is intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation that lawfully can be accorded the appended claims.

Claims

CLAIMS :
The compound of the formula (I) :
CH-j
Figure imgf000021_0001
(I)
wherein R1 is either H or OH and R2 is either H or OH and salts, hydrates and solvates thereof.
2. The compound of claim 1, wherein said compound is lα-hydroxy vitamin D4.
3. The compound of claim 1, wherein said compound is
1.24 dihydroxy vitamin D4.
4. The compound of claim 1, wherein said compound is
1.25 dihydroxy vitamin D4.
5. The compound of claim 1, wherein said compound is biologically active.
6. The compound of formula (I) according to claim 1, wherein R1 is H or OH and R2 is H or OH and wherein said compound exhibits biological activity approaching that of 1,25 vitamin D3 and wherein said compound is less toxic than lα-hydroxy vitamin D3 as determined by comparative LD50 values in rats.
7. The compound of claim 6, wherein said compound is lα-hydroxy vitamin D4.
8. The compound of claim 6, wherein said compound is 1,25 dihydroxy vitamin D4.
9. The compound of claim 6, wherein said compound is 1,24 dihydroxy vitamin D4.
10. The vitamin D4 tosylate compound of the formula (X) :
Figure imgf000022_0001
(X)
11. The 3,5 cyclovitamin D4 compound of the formula (XI)
Figure imgf000022_0002
(XI)
12. The lα-hydroxy 3,5 cyclovitamin D4 of the formula (XII) :
Figure imgf000023_0001
(XII,
13. A pharmaceutical composition, comprising an amount effective to increase serum calcium in a patient suffering vitamin D deficiency of a compound of the formula (I) :
CH3
Figure imgf000023_0002
(1)
wherein Rl is either H or OH and R2 is either H or OH in combination with a pharmaceutically acceptable vehicle.
14. The pharamaceutical composition of claim 13, wherein said amount is administered orally.
15. A method of treating vitamin D deficiency induced diseases comprising administering to a patient suffering therefrom an amount effective to treat the deficiency of a compound of the formula (I) :
Figure imgf000024_0001
(I)
wherein Rl is either H or OH and R2 is either H or OH.
16. A method of preparing lα-hydroxy vitamin D4, comprising:
(a) tosylating vitamin D4 to form vitamin D4 tosylate;
(b) solvolyzing the vitamin D4 tosylate to form 3,5 cyclovitamin D4;
(c) oxidizing the 3,5 cyclovitamin D4 to form lα-hydroxy 3,5 cyclovitamin D4; and
(d) sequentially solvolyzing and subjecting to a Diels-Alder reaction the lα-hydroxy-3 ,5 cyclovitamin D4 to form lα-hydroxy vitamin D4.
17. A method for treating hypocalcemia in a mammal, comprising administering to a mammal an amount, effective to increase serum calcium in the mammal, of a compound having the formula (I) :
Figure imgf000025_0001
(I) wherein Rl is either H or OH and R2 is either H or OH.
18. The method of claim 17, wherein said mammal suffers a vitamin D deficiency.
19. The method of claim 17, wherein said compound is administered in a daily dose of about 0.04 μg to about 1.5 μg per kg of body weight of the treated mammal.
20. The method of claim 17, wherein the hypocalcemia is vitamin D dependent rickets, hypoparathyroidism, post-operative renal osteodystrophy, liver cirrhosis, or steatorrhoea.
21. A method of producing vitamin D tosylate, comprising reacting vitamin D4 with toluenesulfonyl chloride in the presence of dry pryridine.
22. A method of producing 3,5 cyclovitamin D4, comprising subjecting vitamin D4 tosylate to buffered solvolysis.
23. A method of producing lα-hydroxy 3,5 cyclovitamin D4, comprising allylically oxidizing the 3,5 cyclovitamin D4 with selenium dioxide.
24. A method of producing lα-hydroxy vitamin D4, comprising solvolizing the lα-hydroxy 3,5 cyclovitamin D4 with a mixture of dimethylsulfoxide and an organic acid to form an admixture of the 5,6 cis lα-hydroxy and 5,6 trans lα-hydroxy vitamin D4 and subjecting the admixture to a Diels-Alder reaction forming an adduct of the 5,6 trans lα-hydroxy vitamin D4 to yield the lα-hydroxy vitamin D4.
25. A method of producing lα-hydroxy vitamin D4, comprising: reducing ergosterol to 22,23 dihydroxyergosterol, irradiating the 22,23 dihydroxyergosterol to form vitamin D4, and hydroxylating vitamin D4 to form lα-hydroxy vitamin D4.
26. A method of producing lα-hydroxy vitamin D4, comprising:
(a) acetylating ergosterol to form ergosteryl acetate;
(b) hydroxyhalogenating the ergosteryl acetate to form 3?-acetoxy-6α-chloroergosta-7,22-dien-5α-ol;
(c) reducing and reacylating the 3β-acetoxy-6α-ergosta- 7,22-dien-5α-ol to 30-acetoxyergosta-7,22-dien-5α-ol;
(d) hydrogenating the 33-acetoxyergosta-7,22-dien-5α-ol to form 33-acetoxyergsto-7-en-5α-ol;
(e) reducing the 33-acetoxyergsto-7-en-5α-ol to form 22,23 dihydroergosteryl acetate;
(f) reducing the 22,23 dihydroergosteryl acetate to 22,23 dihydroergosterol;
(g) irradiating 22,23 dihydroergosterol to form vitamin D4; (h) tosylating vitamin D4 in the presence of dry pryridine to form vitamin D4 tosylate; (i) solvolyzing vitamin D4 tosylate to form
3.5 cyclovitamin D4;
(j) allylically oxidizing the 3,5 cyclovitamin D4 with selenium dioxide to form lα-hydroxy vitamin D4; and
(k) solvolyzing the lα-hydroxy 3,5 cyclovitamin D4 with a mixture of dimethylsulfoxide and an organic acid to form an admixture of the 5,6 cis lα-hydroxy and
5.6 trans lα-hydroxy vitamin D4 and forming a Diels-Alder adduct of the 5,6 trans lα-hydroxy vitamin D4 to yield lα-hydroxy vitamin D4.
27. A pharmaceutical composition for controlling calcium metabolism comprising a physiologically acceptable vehicle and an effective amount of at least one compound of formula (I)
Ch-<
Figure imgf000027_0001
wherein Rl is either H or OH and R2 is either H or OH.
28. A prophylactic or therapeutic pharmaceutical composition for vitamin D deficient diseases, comprising a physiologically acceptable vehicle and an effective amount of at least one compound of formula (I) :
Figure imgf000027_0002
Figure imgf000027_0003
(I) wherein Rl is either H or OH and R2 is either H or OH.
29. A method of controlling calcium metabolism in a mammal, comprising administering to a mammal a pharmaceutically effective amount of a compound of formula (I)
Figure imgf000028_0001
(I)
wherein Rl is either H or OH and R2 is either H or OH.
30. The method of claim 30, wherein said administering step is done orally, intramuscularly or intravenously.
31. The method of claim 30, wherein the effective amount is about 0.04 μg to about 1.5 μg per kg of body weight of the treated mammal.
32. A feed for mammals comprising at least one compound of the formula (I) wherein Rl is either H or OH and R2 is either H or OH wherein normal consumption of the feed by the mammals provides about 0.01 to about 0.5 μg/kg/day of said compound.
33. A pharmaceutical composition, comprising, an amount, effective to treat abnormal calcium metabolism in a mammal suffering from vitamin D deficiency, of a compound of the
formula (I) :
Figure imgf000029_0001
(i
wherein R., is either H or OH and R2 is either H or OH in combination with a pharmaceutically acceptable vehicle.
34. A method for treating vitamin D deficiency-induced hypocalcemia, comprising:
(a) reducing ergosterol, under such conditions and in sufficient quantity to produce
22,23 dihydroergosterol;
(b) irradiating the 22,23 dihydroergosterol to produce vitamin D4;
(c) hydroxylating the vitamin D4 under such conditions and in sufficient quantity to produce lα-hydroxy vitamin D4;
(d) purifying the vitamin D4; and
(e) administering to a mammal suffering from vitamin D deficiency-induced hypocalcemia an amount effective to increase serum calcium of lα-hydroxy vitamin D4 in admixture with a pharmaceutically acceptable vehicle.
35. A pharmaceutical composition for treating osteoporosis comprising a physiologically acceptable vehicle and an effective amount of a compound of the formula (I)
Figure imgf000030_0001
(I) wherein Rl is either H or OH and R2 is either H or OH.
36. A method of treating osteoporosis, comprising administering to a patient suffering therefrom an amount effective to treat the osteoporosis of a compound of the formula
(I):
Figure imgf000030_0002
(I)
wherein Rl is either H or OH and R2 is either H or OH.
PCT/US1991/006865 1990-09-21 1991-09-20 NOVEL 1α-HYDROXY VITAMIN D4 AND NOVEL INTERMEDIATES AND ANALOGUES WO1992005130A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR919106062A BR9106062A (en) 1990-09-21 1991-09-20 NOVA 1 ALPHA-HYDROXY VITAMIN D4 AND NEW INTERMEDIARIES AND ANALOGS
PL91294706A PL170447B1 (en) 1990-09-21 1991-09-20 Method of obtaining novel 1 alpha-hydroxyvitamin d4 and novel transition and analog compounds
KR1019920701187A KR100231809B1 (en) 1990-09-21 1991-09-20 Novel 1-alpha hydroxy vitamin d4 and novel intermediates and analogues
CA002069084A CA2069084C (en) 1990-09-21 1991-09-20 1.alpha.-hydroxy vitamin d4 and novel intermediates and analogues
DK91917288T DK0503035T3 (en) 1990-09-21 1991-09-20 Newly known 1alpha-hydroxy vitamin D4 and novel intermediates and analogues
DE69132862T DE69132862T2 (en) 1990-09-21 1991-09-20 NEW 1ALPHA-HYDROXY VITAMIN-D4 AND NEW INTERMEDIATE PRODUCTS AND ANALOGS
AU85422/91A AU650286B2 (en) 1990-09-21 1991-09-20 Novel 1alpha-hydroxy vitamin D4 and novel intermediates and analogues
EP91917288A EP0503035B1 (en) 1990-09-21 1991-09-20 Novel 1alpha-hydroxy vitamin d4 and novel intermediates and analogues
NO92921955A NO921955L (en) 1990-09-21 1992-05-18 NEW VITAMIN D-COMPOUNDS AND PROCEDURES FOR PREPARING THE SAME

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58685490A 1990-09-21 1990-09-21
US586,854 1990-09-21

Publications (1)

Publication Number Publication Date
WO1992005130A1 true WO1992005130A1 (en) 1992-04-02

Family

ID=24347363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006865 WO1992005130A1 (en) 1990-09-21 1991-09-20 NOVEL 1α-HYDROXY VITAMIN D4 AND NOVEL INTERMEDIATES AND ANALOGUES

Country Status (18)

Country Link
US (1) US5488120A (en)
EP (1) EP0503035B1 (en)
KR (1) KR100231809B1 (en)
CN (3) CN1032255C (en)
AR (1) AR247817A1 (en)
AU (1) AU650286B2 (en)
BR (1) BR9106062A (en)
CA (1) CA2069084C (en)
DE (1) DE69132862T2 (en)
DK (1) DK0503035T3 (en)
ES (1) ES2169023T3 (en)
HU (2) HU213471B (en)
MX (1) MX9101224A (en)
NO (1) NO921955L (en)
NZ (1) NZ239897A (en)
PL (1) PL170447B1 (en)
WO (1) WO1992005130A1 (en)
ZA (1) ZA917553B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562497A1 (en) * 1992-03-27 1993-09-29 Nisshin Flour Milling Co., Ltd. 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions
EP0631500A1 (en) * 1992-01-29 1995-01-04 Bone Care International, Inc. 1 alpha-HYDROXY-24-(EPI)-VITAMIN D4
WO1996031215A1 (en) * 1995-04-03 1996-10-10 Bone Care International, Inc. Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
WO1996040153A1 (en) * 1995-06-07 1996-12-19 Bone Care International, Inc. Use of vitamin d4 derivatives for treating cancer
WO1996040154A1 (en) * 1995-06-07 1996-12-19 Bone Care International, Inc. Use of vitamin d4 derivatives for treating skin disorders
US5756783A (en) * 1990-09-21 1998-05-26 Bone Care International, Inc. 1α-Hydroxy-24-EPI-vitamin D4
WO1999061398A2 (en) * 1998-05-29 1999-12-02 Bone Care International 24-hydroxyvitamin d, analogs and uses thereof
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6929797B2 (en) 1997-02-13 2005-08-16 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
NZ254424A (en) * 1992-06-22 1997-09-22 Lunar Corp Pharmaceutical composition and use of 1 alpha hydroxy-pre-vitamin d
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6900191B1 (en) 1997-02-25 2005-05-31 Oncquest, Inc. 1α-Hydroxyvitamin D5, its synthesis and use in cancer prevention
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
ES2368824T3 (en) * 1998-03-27 2011-11-22 Oregon Health & Science University VITAMIN D AND ITS ANALOGS IN THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATIVE DISORDERS.
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
JP2005504279A (en) * 2001-09-27 2005-02-10 ザ・コカ−コーラ・カンパニー Vitamin fortification of food
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
WO2005102355A1 (en) * 2004-04-23 2005-11-03 Genzyme Corporation METHODS OF TREATING VARIOUS VITAMIN D METABOLISM CONDITIONS WITH 1α-HYDROXYVITAMIN D2
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
CN108663442B (en) * 2017-12-30 2021-03-30 南京海融制药有限公司 Method for checking related substances of alfacalcidol tablet
CN108218750B (en) * 2017-12-30 2019-09-10 南京海融制药有限公司 A kind of directional synthesis method of isomer impurities of Alfacalcidol and application thereof
CN108047108B (en) * 2017-12-30 2019-09-20 南京海融制药有限公司 A kind of relative substance PZB of Alfacalcidol and its preparation method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202859A (en) * 1976-09-28 1980-05-13 Aktieselskabet De Danske Sukkerfabrikker Crystallizer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2383446A (en) * 1941-06-04 1945-08-28 Du Pont Antirachitic materials and processes for their production
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
NL188286C (en) * 1978-01-16 1992-05-18 Wisconsin Alumni Res Found PROCESS FOR PREPARING A 1-ALFA-HYDROXYVITAMINE D COMPOUND
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4661294A (en) * 1985-03-18 1987-04-28 The General Hospital Corporation Biologically active 1-thio derivatives of vitamin D
US4866048A (en) * 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
JP2550391B2 (en) * 1988-06-30 1996-11-06 日清製粉株式会社 Method for producing 1β-hydroxyvitamin D 2 below and D 3 below
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
JP2645130B2 (en) * 1989-03-31 1997-08-25 日清製粉株式会社 Steroid derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202859A (en) * 1976-09-28 1980-05-13 Aktieselskabet De Danske Sukkerfabrikker Crystallizer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DELUCA et al. Arch. Biochem. and Biophys. 124, 122-128 (1968) Synthesis, Biological Activity and Metabolism of 22,23 3H Vitamin D4. *
See also references of EP0503035A4 *
WINDAVS et al. 2. Physiol. Chem. 247, 1937, pp. 185 to 188. Ueber das Krystallisierte Vitamin D4. *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756783A (en) * 1990-09-21 1998-05-26 Bone Care International, Inc. 1α-Hydroxy-24-EPI-vitamin D4
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
EP0631500A1 (en) * 1992-01-29 1995-01-04 Bone Care International, Inc. 1 alpha-HYDROXY-24-(EPI)-VITAMIN D4
EP0631500A4 (en) * 1992-01-29 1995-08-30 Lunar Corp 1-g(a)-HYDROXY-24--i(EPI)-VITAMIN D 4?.
AU682817B2 (en) * 1992-01-29 1997-10-23 Bone Care International, Inc. 1alpha-hydroxy-24-(epi)-vitamin D4
EP0562497A1 (en) * 1992-03-27 1993-09-29 Nisshin Flour Milling Co., Ltd. 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
WO1996031215A1 (en) * 1995-04-03 1996-10-10 Bone Care International, Inc. Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
WO1996040153A1 (en) * 1995-06-07 1996-12-19 Bone Care International, Inc. Use of vitamin d4 derivatives for treating cancer
AU718625B2 (en) * 1995-06-07 2000-04-20 Bone Care International, Inc. Use of vitamin D4 derivatives for treating cancer
WO1996040154A1 (en) * 1995-06-07 1996-12-19 Bone Care International, Inc. Use of vitamin d4 derivatives for treating skin disorders
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6680309B2 (en) 1996-12-30 2004-01-20 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6929797B2 (en) 1997-02-13 2005-08-16 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
WO1999061398A3 (en) * 1998-05-29 2000-11-23 Bone Care Internat 24-hydroxyvitamin d, analogs and uses thereof
WO1999061398A2 (en) * 1998-05-29 1999-12-02 Bone Care International 24-hydroxyvitamin d, analogs and uses thereof

Also Published As

Publication number Publication date
HU213471B (en) 1997-06-30
DE69132862D1 (en) 2002-01-24
EP0503035A4 (en) 1994-03-30
KR100231809B1 (en) 1999-12-01
PL294706A1 (en) 1993-10-04
US5488120A (en) 1996-01-30
MX9101224A (en) 1992-05-04
ZA917553B (en) 1992-07-29
CN1061220A (en) 1992-05-20
AU8542291A (en) 1992-04-15
BR9106062A (en) 1993-03-09
ES2169023T3 (en) 2002-07-01
CN1130507A (en) 1996-09-11
DE69132862T2 (en) 2002-08-29
CN1032255C (en) 1996-07-10
AU650286B2 (en) 1994-06-16
CA2069084A1 (en) 1992-03-22
CN1136433A (en) 1996-11-27
EP0503035B1 (en) 2001-12-12
KR920703487A (en) 1992-12-18
EP0503035A1 (en) 1992-09-16
DK0503035T3 (en) 2002-04-15
PL170447B1 (en) 1996-12-31
AR247817A1 (en) 1995-04-28
NZ239897A (en) 1996-03-26
CA2069084C (en) 2007-05-22
HU9201691D0 (en) 1992-09-28
HUT62559A (en) 1993-05-28
NO921955D0 (en) 1992-05-18
HU211963A9 (en) 1996-01-29
NO921955L (en) 1992-06-05

Similar Documents

Publication Publication Date Title
EP0503035B1 (en) Novel 1alpha-hydroxy vitamin d4 and novel intermediates and analogues
US5763428A (en) Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
US5798345A (en) Method of inhibiting the hyperproliferation of malignant cells
EP0914825B1 (en) Methods for preparation of 1 alpha, 24-dihydroxy vitamin D2
US5789397A (en) Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
EP0614456B1 (en) 1alpha,24(s)-dihydroxy vitamin d2, its formation and use
US6025346A (en) 1α-hydroxy vitamin D4 and novel intermediates and analogues
US5801164A (en) Methods of treating osteoporosis prophylactically or therapeutically
US20040009958A1 (en) Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US6166000A (en) Methods for preparation and use of 1α,24(S)-Dihydroxy vitamin . D.sub2
US5354744A (en) Side chain unsaturated 1 alpha-hydroxyvitamin D analogs
US6251883B1 (en) Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
Knutson et al. 1 alpha-hydroxy vitamin D4 and novel intermediates and analogues
MXPA97009684A (en) Use of vitamin d4 derivatives for treatment of p disorders
MXPA97009683A (en) Use of vitamin d4 derivatives for treatment against the can
AU6301699A (en) Methods for preparing and use of 1alpha,24(S)-dihydroxy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA HU JP KP KR NO PL SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2069084

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991917288

Country of ref document: EP

WR Later publication of a revised version of an international search report
WWP Wipo information: published in national office

Ref document number: 1991917288

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991917288

Country of ref document: EP